1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Refractory Triple-Negative Breast Carcinoma: new trials by email Literature Review of Refractory Triple-Negative Breast Carcinoma trials Research Report on Refractory Triple-Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Emory University | 37 | 2024-09-01 | 2026-06-04 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Olaparib, Onalespib - Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 28 | 2017-05-19 | 2023-04-26 |
Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Neoplasm Metastasis (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Breast Neoplasms (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · Biopsy (1) · Propranolol (1) · Specimen Handling (1) · olaparib (1) · pembrolizumab (1)
Emory University (1) · National Cancer Institute (NCI) (1)
United States (2)
Panagiotis A Konstantinopoulos (1) · Shipra Gandhi, MD, MS (1)
K08CA279766 (1), UM1CA186709 (1)